Oral melatonin in neurologically disabled children (multiple letters) [6]

Lancet

Volumn 351, Issue 9120, 1998, Pages 1963-1964

  Manev, H ^a   Uz, T ^a   Wurtman, R J ^a   Zhdanova, I I ^a   Sheldon, S H ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MELATONIN;

ANTICONVULSANT ACTIVITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG MECHANISM; HUMAN; LETTER; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SEIZURE; ANIMAL; CHEMICALLY INDUCED DISORDER; CHILD; NOTE; ORAL DRUG ADMINISTRATION; RAT;

ADMINISTRATION, ORAL; ANIMALS; CHILD; HUMANS; MELATONIN; NERVOUS SYSTEM DISEASES; RATS; SEIZURES;

EID: 17144474270     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0140-6736(05)78652-9     Document Type: Letter

References (3)

1. SH Sheldon Pro-convulsant effects of oral melatonin in neurologically disabled children Lancet 351 1998 1254
2. AB Dollins IV Zhdanova RJ Wurtman HJ Lynch MH Deng Effect of inducing nocturnal serum melatonin concentrations in daytime on sleep, mood, body temperature, and performance Proc Natl Acad Sci 91 1994 1824 1828
3. IV Zhdanova J Wagstaff RJ Wurtman Melatonin and sleep in Angelman syndrome children 1996 American Sleep Disorders Association (APSS) Sleep Research Society Washington 29 10th Annual Meeting (abstr 58)